These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29999301)

  • 1. Mass Spectrometry Reveals a Multifaceted Role of Glycosaminoglycan Chains in Factor Xa Inactivation by Antithrombin.
    Minsky BB; Abzalimov RR; Niu C; Zhao Y; Kirsch Z; Dubin PL; Savinov SN; Kaltashov IA
    Biochemistry; 2018 Aug; 57(32):4880-4890. PubMed ID: 29999301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet factor 4 neutralizes heparan sulfate-enhanced antithrombin inactivation of factor Xa by preventing interaction(s) of enzyme with polysaccharide.
    Fiore MM; Kakkar VV
    Biochem Biophys Res Commun; 2003 Nov; 311(1):71-6. PubMed ID: 14575696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate heparin-antithrombin-factor Xa bridging complex. Demonstration by rapid kinetics studies.
    Rezaie AR; Olson ST
    Biochemistry; 2000 Oct; 39(39):12083-90. PubMed ID: 11009624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutagenesis studies toward understanding the mechanism of differential reactivity of factor Xa with the native and heparin-activated antithrombin.
    Rezaie AR; Yang L; Manithody C
    Biochemistry; 2004 Mar; 43(10):2898-905. PubMed ID: 15005625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets.
    Stevic I; Chan HH; Chander A; Berry LR; Chan AK
    Thromb Haemost; 2013 Jun; 109(6):1016-24. PubMed ID: 23494009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural glycobiology of heparin dynamics on the exosite 2 of coagulation cascade proteases: Implications for glycosaminoglycans antithrombotic activity.
    Pol-Fachin L; Verli H
    Glycobiology; 2014 Jan; 24(1):97-105. PubMed ID: 24201825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of designed sulfated flavanoids with antithrombin: lessons on the design of organic activators.
    Gunnarsson GT; Desai UR
    J Med Chem; 2002 Sep; 45(20):4460-70. PubMed ID: 12238925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio.
    Moore GW; de Jager N; Cutler JA
    Thromb Res; 2015 Jan; 135(1):161-6. PubMed ID: 25466846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation.
    Johnson DJ; Li W; Adams TE; Huntington JA
    EMBO J; 2006 May; 25(9):2029-37. PubMed ID: 16619025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational equilibrium of the reactive center loop of antithrombin examined by steady state and time-resolved fluorescence measurements: consequences for the mechanism of factor Xa inhibition by antithrombin-heparin complexes.
    Futamura A; Beechem JM; Gettins PG
    Biochemistry; 2001 Jun; 40(22):6680-7. PubMed ID: 11380263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin conformational modulation by D-myo-inositol 3,4,5,6-tetrakisphosphate (TMI), a novel scaffold for the development of antithrombotic agents.
    Arantes PR; Pérez-Sánchez H; Verli H
    J Biomol Struct Dyn; 2018 Nov; 36(15):4045-4056. PubMed ID: 29173042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin.
    Whinna HC; Lesesky EB; Monroe DM; High KA; Larson PJ; Church FC
    J Thromb Haemost; 2004 Jul; 2(7):1127-34. PubMed ID: 15219196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel strategy to generate biologically active neo-glycosaminoglycan conjugates.
    Rong J; Nordling K; Björk I; Lindahl U
    Glycobiology; 1999 Dec; 9(12):1331-6. PubMed ID: 10561458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-binding exosite of factor Xa.
    Rezaie AR
    Trends Cardiovasc Med; 2000 Nov; 10(8):333-8. PubMed ID: 11369259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixolaris: a factor Xa heparin-binding exosite inhibitor.
    Monteiro RQ; Rezaie AR; Ribeiro JM; Francischetti IM
    Biochem J; 2005 May; 387(Pt 3):871-7. PubMed ID: 15617517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
    Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
    Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The critical role of hinge-region expulsion in the induced-fit heparin binding mechanism of antithrombin.
    Langdown J; Belzar KJ; Savory WJ; Baglin TP; Huntington JA
    J Mol Biol; 2009 Mar; 386(5):1278-89. PubMed ID: 19452598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths.
    Wagenvoord R; Al Dieri R; van Dedem G; Béguin S; Hemker HC
    Thromb Res; 2008; 122(2):237-45. PubMed ID: 18045667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The region of antithrombin interacting with full-length heparin chains outside the high-affinity pentasaccharide sequence extends to Lys136 but not to Lys139.
    Arocas V; Turk B; Bock SC; Olson ST; Björk I
    Biochemistry; 2000 Jul; 39(29):8512-8. PubMed ID: 10913257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.